Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 2/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966663 | 0.86 | MAPT (0.56) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL11221807 | 0.86 | PRKCE (0.42) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL28692424 | 0.78 | CYP4F2 (0.61) | FAAHMAPT | |
| SCHEMBL266233 | 0.78 | CYP4F2 (0.61) | FAAHMAPT | |
| SCHEMBL4267520 | 0.77 | MAPT (0.51) | FAAHALDH1A1MAPTHPGDCNR1 | |
| SCHEMBL6498274 | 0.77 | TERT (0.55) | FAAHMAPT | |
| SCHEMBL1679203 | 0.77 | TERT (0.55) | FAAHMAPT | |
| SCHEMBL5048759 | 0.77 | TERT (0.55) | FAAHMAPT | |
| SCHEMBL1679205 | 0.77 | TERT (0.55) | FAAHMAPT | |
| SCHEMBL16424239 | 0.77 | MAPT (0.38) | FAAHMAPTCNR1CNR2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658238-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF APIXABAN | TAP Pharmaceuticals AG (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-12290504-B2 | Aqueous formulations of topiramate | TAP PHARMACEUTICALS AG (CH) | 2025-05-06 | — | — | US | disclosed |
| US-20240342132-A1 | AQUEOUS FORMULATIONS OF TOPIRAMATE | TAP PHARMACEUTICALS, AG (CH) | 2024-10-17 | — | — | US | disclosed |
| WO-2024213638-A1 | AQUEOUS FORMULATIONS OF TOPIRAMATE | TAP PHARMACEUTICALS AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-12109188-B1 | Liquid pharmaceutical formulations of topiramate | XAVION LIFESCIENCES, LLC | 2024-10-08 | — | — | US | disclosed |
| US-20240325349-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF TOPIRAMATE | TAP PHARMACEUTICALS, AG (CH) | 2024-10-03 | — | — | US | disclosed |
| WO-2024200299-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF TOPIRAMATE | TAP PHARMACEUTICALS AG (CH) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024160789-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF APIXABAN | TAP PHARMACEUTICALS AG (CH) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342132-A1 | AQUEOUS FORMULATIONS OF TOPIRAMATE | SORD, GK, SI | FAAH 351/4885ALDH1A1 564/4885MAPT 574/4885 |
| US-12290504-B2 | Aqueous formulations of topiramate | SORD, GK, SI | FAAH 351/4885ALDH1A1 564/4885MAPT 574/4885 |
| US-12109188-B1 | Liquid pharmaceutical formulations of topiramate | GK, GAPDH, SCD | FAAH 47/4885ALDH1A1 416/4885MAPT 42/4885 |
| US-20240325349-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF TOPIRAMATE | GK, GAPDH, SCD | FAAH 47/4885ALDH1A1 416/4885MAPT 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.